Search results
Results from the WOW.Com Content Network
Novo Nordisk's decision to stop selling its long-acting insulin Levemir in the United States has left some diabetes patients struggling to switch treatments, patients and doctors in a dozen U.S ...
The top of executive of Novo Nordisk told a Senate panel Tuesday it was a "difficult choice" to discontinue the long-acting insulin Levemir but he had to do so because of market forces.
The announcement comes eight months after Novo said it would cut U.S. list prices for several of its insulin products next year, including a 65% reduction in the list price of Levemir, in response ...
Novo Nordisk will meet with the aides for Senators Jeanne Shaheen, Raphael Warnock, and Elizabeth Warren. ... Sales of Novo's other long-acting insulin Tresiba were 1.33 billion crowns last year ...
By Sriparna Roy and Mariam Sunny (Reuters) -Advisers to the U.S. health regulator on Friday voted against the use of Novo Nordisk's weekly insulin in patients with type 1 diabetes due to risks of ...
The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee is scheduled to meet on May 24 to review Novo Nordisk A/S’s (NYSE:NVO) application seeking approval for a once-weekly insulin ...
Eli Lilly's GLP-1 drugs - Zepbound approved for weight loss and Mounjaro for diabetes - compete with Novo Nordisk's Wegovy and Ozempic. Lilly also uses Catalent for GLP-1 and diabetes drug production.
(Reuters) -U.S. President Joe Biden and Senator Bernie Sanders called on Novo Nordisk and Eli Lilly to reduce the prices of their weight-loss and diabetes drugs, in a jointly authored opinion ...